Life sciences business Avacta sees revenues rise 26%
Life sciences business Avacta reported a 26% rise in revenue for the year to the end of July, to £2.74m, as its CEO hailed an “exceptionally strong” 12 months for the group.
However, loss from continuing operations rose to £6.37m, up from £4.65m in 2016, while the loss per share increased to 9.31p from 6.86p the year before.
The group had cash balances at £13.17m, which Avacta said was “well ahead” of market expectations.
The Wetherby-based group, which has been concentrating on developing Affimers, an engineered ... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...
